Memory Pharmaceuticals delays MEM 3454 Alzheimer's program

By Elaine Rigoli

Tampa, Fla., June 1 - Memory Pharmaceuticals Corp. is delaying the start of its phase 2a clinical trial of MEM 3454, the company's lead nicotinic alpha-7 receptor partial agonist, in Alzheimer's disease.

This delay is based on feedback from the Food and Drug Administration concerning the potential for impurities in the clinical material that the company proposed for use in the phase 2a trial, originally expected to begin in June and now expected to commence later this year.

Memory Pharmaceuticals is a biopharmaceutical company based in Montvale, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.